日本化学療法学会雑誌第57巻第1号
|
|
- こおが おうじ
- 5 years ago
- Views:
Transcription
1 In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae In vitro
2 Concentration of levofloxacin ( g/ml) Fig.. Simulatedbloodconcentrationoflevofloxacininanin vitropharmacokineticmodel. Opencircles,00mgt.i.d.;closeddiamonds,00mgq.d.; dotedlinewithasterisks,0mgq.d.;dotedlinewith closedtriangles,0mgb.i.d. in vitro I S. pneumoniae µ E. coli β β In vitro S. pneumoniae E. coli S. pneumoniae E.coli S. pneumoniae
3 S. pneumoniae E. coli S. pneumoniae gyra gyrb parc pare S. pneumoniae gyra gyrb parc pare E. coli gyra gyrb parc pare S. pneumoniae µ E. coli β µ II In vitro S. pneumoniae S. pneumoniae µ S. pneumoniae
4 (A) (C) (B) (D) (E) (F) (G) Fig.. BactericidalactivityoflevofloxacinagainstclinicalisolatesofStreptococcuspneumoniaeinaninvitro pharmacokineticmodel. (A)S.pneumoniaeEG00,(B)S.pneumoniaeEG000,(C)S.pneumoniaeEG00,(D)S.pneumoniae EG00,(E)S.pneumoniaeEG00,(F)S.pneumoniaeEG00,(G)S.pneumoniaeEG00.Opencircles, 00mgt.i.d.;closeddiamonds,00mgq.d.;solidline,growthcontrol,dotedline;detectionlimit. µ
5 S. pneumoniae E. coli (A) Levofloxacin ( g/ml) (C) Levofloxacin ( g/ml) (B) Levofloxacin ( g/ml) (D) Levofloxacin ( g/ml) (E) Levofloxacin ( g/ml) (F) Levofloxacin ( g/ml) (G) Levofloxacin ( g/ml) Fig.. FrequencyofresistantpopulationinclinicalisolatesofStreptococcuspneumoniaeaftersimulating bloodconcentrationoflevofloxacin. (A)S.pneumoniaeEG00,(B)S.pneumoniaeEG000,(C)S.pneumoniaeEG00,(D)S.pneumoniae EG00,(E)S.pneumoniaeEG00,(F)S.pneumoniaeEG00,(G)S.pneumoniaeEG00.Opencir cles,00mgt.i.d.;closeddiamonds,00mgq.d.;solidline,controlwithnodrugtreatment,dotedline; detectionlimit. S. pneumoniae µ µ µ
6 Table. Pharmacokinetic/pharmacodynamicparametersandbactericidalefectoflevofloxacinin00mgt.i.d.and00mgq.d.models instreptococcuspneumoniae StrainNo. DetailedMIC a (μ g/ml) Simulation model AUC/MIC Cmax/MIC LogofCFU/mL at0h LogofCFU/mL ath Degreein population analysis b EG00 EG000 EG00 EG00 EG00 EG00 EG mgt.i.d. 00mgq.d. 00mgt.i.d. 00mgq.d. 00mgt.i.d. 00mgq.d. 00mgt.i.d. 00mgq.d. 00mgt.i.d. 00mgq.d. 00mgt.i.d. 00mgq.d. 00mgt.i.d. 00mgq.d a :MICwastestedtimesandtheaveragecalculated. b :Degreeofthesusceptibilityreductiontolevofloxacinath. S. pneumoniae E. coli E. coli E. coli µ E. coli µ µ µ E. coli µ E. coli E. coli E. coli
7 S. pneumoniae E. coli (A) (C) (B) (D) (E) Fig.. BactericidalactivityoflevofloxacinagainstclinicalisolatesofEscherichiacoliinaninvitropharmacoki neticmodel. (A)E.coliGK000,(B)E.coliGK00,(C)E.coliGK000,(D)E.coliGK00,(E)E.coliGK00.Open circles,00mgt.i.d.;dotedlinewithasterisks,0mgq.d.;dotedlinewithclosedtriangles,0mgb.i.d.; closeddiamonds,00mgq.d.;solidline,growthcontrol. E. coli S. pneumoniae S. pneumoniae
8 (A) (B) LVFX ( g/ml) LVFX ( g/ml) (C) LVFX ( g/ml) (D) LVFX ( g/ml) (E) LVFX ( g/ml) Fig.. FrequencyofresistantpopulationinclinicalisolatesofEscherichiacoliaftersimulatingbloodconcen trationoflevofloxacin. (A)E.coliGK000,(B)E.coliGK00,(C)E.coliGK000,(D)E.coliGK00,(E)E.coliGK00.Open circles,00mgt.i.d.;dotedlinewithasterisks,0mgq.d.;dotedlinewithclosedtriangles,0mgb.i.d.; closeddiamonds,00mgq.d.;solidline,controlwithnodrugtreatment,dotedline;detectionlimit. S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae
9 S. pneumoniae E. coli Table. Pharmacokinetic/pharmacodynamicparametersandbactericidalefectoflevofloxacinin00mgt.i.d.,0mgq.d.,0mg b.i.d.,and00mgq.d.modelsinescherichiacoli StrainNo. DetailedMIC a (μ g/ml) Simulation model AUC/MIC Cmax/MIC LogofCFU/mL at0h LogofCFU/mL ath Degreein population analysis b GK mgt.i.d. 0mgq.d. 00mgq.d GK mgt.i.d. 0mgq.d. 00mgq.d GK mgt.i.d. 0mgq.d. 0mgb.i.d. 00mgq.d GK mgt.i.d. 0mgq.d. 0mgb.i.d. 00mgq.d GK00. 00mgt.i.d. 0mgq.d. 0mgb.i.d. 00mgq.d a :MICwastestedtimesandtheaveragewascalculated. b :Degreeofthesusceptibilityreductiontolevofloxacinath. Table. MICswithorwithoutreserpineandaminoacidsubstitutionsintheQRDRaftertreatmentwithlevofloxacin00mgt.i.d. model Isolate EG000 ParC Aminoacidsubstitution ParE GyrA Levofloxacin MIC(μ g/ml) Alone Ciprofloxacin + Reserpine LVFX/EG000- a Ser Tyr LVFX/EG000- Asp Asn EG00 LVFX/EG00- LVFX/EG00- LVFX/EG00- EG00 LVFX/EG00- LVFX/EG00- LVFX/EG00- EG00 LVFX/EG00- LVFX/EG00- EG00 LVFX/EG00- LVFX/EG00- Asp Asn Ser Tyr Asp Tyr Asp Tyr Asp Asn Ser Phe Asp Asn Ser Phe a :LVFX,isolateaftertreatmentwithlevofloxacin00mgt.i.d.model. b :Valueslistedarereduction(n-fold)inMICofciprofloxacinwithadditionofreserpine(0μ g/ml) Ratio b E. coli E. coli
10 Table. MICswithorwithoutPAβ NandaminoacidsubstitutionsintheQRDRaftertreatmentwith levofloxacin00mgt.i.d.modelor0mgq.d.model Isolate GK00 LVFX/GK00 GK000 LVFX/GK000- LVFX/GK000- GK00 LVFX/GK00- LVFX/GK00- GK00 LVFX/GK00 LVFX simulation model a 00mgt.i.d. 00mgt.i.d. 0mgq.d. 00mgt.i.d. 0mgq.d. 0mgq.d. Aminoacidsubstitution GyrA Ser Leu Ser Leu Ser Leu Ser Leu Asp Gly Ser Leu Asp Gly Ser Leu Ser Leu Ser Leu Ser Leu Ser Leu ParC Glu Gly Glu Gly Ser0 Ile Ser0 Ile Ser0 Ile MIC(μ g/ml) Levofloxacin Alone + PAβ N Ratio b a :Notreatment, b :Valueslistedarereduction(n-fold)inMICoflevofloxacinwithadditionofPhe-Arg-β - naphthylamide(paβ N,00μ g/ml). E. coli E. coli E. coli E. coli β β E. coli E. coli III in vitro in vitro S. pneumoniae E. coli S. pneumoniae S. pneumoniae in vitro S. pneumoniae E. coli S. pneumoniae E. coli S. pneumoniae E. coli
11 S. pneumoniae E. coli in vitro Pseudomonas aeruginosa P. aeruginosa E. coli S. pneumoniae S. pneumoniae in vitro S. pneumoniae in vitro E. coli E. coli in vitro E. coli S. pneumoniae S. pneumoniae µ µ S. pneumoniae µ S. pneumoniae µ S. pneumoniae in vitro
12 Streptococcus pneumoniae Streptococcus pneumoniae In vitro Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Pseudomonas aeruginosa Pseudomonas aeruginosa Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Escherichia coli
13 S. pneumoniae E. coli in vitro Escherichia coli Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae gyra gyrb parc pare Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae Streptococcus pneumoniae
14 Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli in vitro µ S. pneumoniae E. coli µ
日本化学療法学会雑誌第57巻第5号
in vitro Key words Streptococcus pneumoniae β Haemophilus influenzae Escherichia coli I Table. Antibacteriallevofloxacinactivityagainstclinicalisolates Organism Year Susceptibility(%)(Numberofstrains)
More information日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
More information日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089
More information日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
More information,...~,.'~ 表 2.6.2.2-26 試験管内 PAE 菌株薬剤 MIC (µg/ml) PAE (h) 1 MIC 4 MIC STFX 0.025 0.92 2.35 S. aureus FDA 209-P LVFX 0.20 0.68 2.68 CPFX 0.20 1.05 1.59 SPFX 0.10 0.35 1.07 STFX 0.025 2.33 1.14 E. coli KL-16
More information内科96巻3号★/NAI3‐1(第22回試験問題)
µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2
More information- 1 -
- 1 - - 1 - ... 1... 2... 4... 5... 9... 11... 14... 16... 20... 21... 22... 23... 23 - 1 - - 2 - - 3 - - 4 - - 5 - - 6 - - 7 - - 8 - - 9 - ( ) - 10 - - 11 - Pseudomonas aeruginosa Escherichia coli Staphylococcus
More informationMIC MIC...
50 mg 10% 2.7.36 2.7.36 2.7.36... 1 1.6... 1 2.6... 3 3.6... 5 3.16... 5 3.26... 12 3.36... 16 4.6... 17 5.6... 19 6.6... 20 2.7.3.3.16-1 MIC... 9 2.7.3.3.16-2 MIC... 10 2.7.3.3.16-3 MIC E. coli... 11
More information日本化学療法学会雑誌第66巻第2号
173 Table 1.Detection rates of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Ureaplasma urealyticum, Haemophilus influenzae and adenovirus from male urethritis in Urethritis No.
More information日本化学療法学会雑誌第55巻第S-1号
µ µ Key words Streptococcus pneu- moniae S. pneumoniae µ µ I γ H H C HN F F O N O CO H H C SO H H O Fig.. ChemicalstructureofGRNX. γ γ II Haemophilus influenzae Pseudomonas aeruginosa Streptococcus intermedius
More information浜松地区における耐性菌調査の報告
平成 28 年度浜松地区感染対策地域連携を考える会 2017 年 2 月 22 日 浜松地区 耐性菌サーベイランス報告 浜松医科大学医学部附属病院 感染対策室 概要 平成 19 年 4 月に施行された改正医療法により すべての医療機関において管理者の責任の下で院内感染対策のための体制の確保が義務化されました 本サーベイランスは 静岡県浜松地区 ( 浜松市 湖西市 ) における薬剤耐性菌の分離状況や薬剤感受性の状況を調査し
More information4月号 学会特集号 122247/16)一般演題目次
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 48 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 49 60 61 62 63 64 65 66 67 68
More information日本化学療法学会雑誌第57巻第4号
Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.
More information2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
More information立命館21_松本先生.indd
2143-552010 1 2 () 1 2 3 456 78- Key Words 1 3 12007 2 3 508 19992008 1 23 4 43 2120107 4 2008 1992 2003 2005 1989 2008 4 2 2-1 10 4 4 6 5 4 5 2946 1 155 11 41 44 45 4 2-2 2003 1 21 2 1 3 4 5 6 7 3 2120107
More information立命館20_服部先生.indd
20 93-105 2010 2 () ' - 1 ( ) ( ' 2005) Key Words 2 1967 93 20 2010 1 94 1 ' 2002 2 2 1996 1996 1999 2 2 2 1993 1999 4 1 2 1985 1989 1986 1994 4 1 2 1 1 4 2 4 4 1 4 1966 4 10-1970 20 1993-1972 95 20 2010
More information1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70
14 2006 1 Key Words 2002 3 1 2 3 3 1 2 3 1969 1987 69 1996 2000 2004 1984 2005 7150 000 9 500 9 4 13 10 95 11 11 12 20002004 9 70 14 2006 1 15 71 72 1 22 6 32 9 200 6 3 1 2 2000 10 1 2003 10 2005 6 5 4
More information立命館16_坂下.indd
1669-792008 1 - ' 85- -108 ' Key words 1 2 2003 69 1620082 5 3 1990 1997 4 5 2001 1307 6 7 1 1 1 1996 100 2 1997 71 3 1998 71 4 1999 96 5 2000 95 6 2001 145 7 2002 191 8 2003 174 9 2004 120 10 2005 122
More information立命館人間科学研究No.10
1 77 5 Key words 1 23 3 11417 14310045 20022004 2 2003 20022005 20022004 2 10200511 3 2003 1152003 59 1995 3 32003 19932002 20032003 2005 20052005 4 1997 2000521986 2001 42001 3 1981 6 1 7 5 1000248 1632647
More information立命館21_川端先生.indd
21 119-132 2010 ( ) ' Key Words 119 21 2010 7 1962 2001 2001 2007 1982 1988 1997 2007 1997 1998 1863 1880 1 1998 1998 2001 1599 120 121 1599 1695 8 1695 1714 4 1714 1715 5 1715 100 1812 9 1812 1864 2001
More information立命館14_前田.indd
1499-1122007 1 ) ) ) ) ) (1) -- ) ) ) ) ) ) ( ) ) ' ) ) ) ) - 1) 2)' 3) Key words 19811994 1721 99 1420073 100 20012004 2005 2004 2002 33 34 10 1987 45 20002003 2002 1 1 2000 1 1 2001 2 200341 12004 2
More information立命館17_坂下.indd
1793-1052008 1 () -- -- - Key words 1 93 1720088 2 3 2003 15 1996 50 3040 2 3 4050 50 10 1980 1995 1950 1958 1968 1972 94 95 1987 4 4 70 3 3 1 2000 2001 4 1720088 96 2001 2003 2 1978 1990 1997 130 2 3
More information立命館人間科学研究No.10
49 00 7 Key words 980 995 50 0005 90 997 99 990 994 99 99 99990 99 996 988988 994 99 995 995 995 994 984 988 986 997 997 00 995 00 5 7 5 5 999 997 997 998 6 998 999 997 997 998 0040000 994 996 000 00 5
More information立命館19_椎原他.indd
191-132009 1 ( ) ' Key Words 1 11 12007 2007 200520062 201120062 7558 4009 1 1920098 2007 2 2000 028 2005 1999 12 1999 13 1968 2 3 '1992 2007 2001 20052001 1977 2005 2005 2007 21 21 22 461927 3 13 1920098
More information立命館人間科学研究No.10
61 10 1990 Key words 1 102005 11 62 2000 1 1920 10 1892 63 1 1 19 100 1914 100 1 1 20 1 2 102005 11 64 1946 21 4 1947 1949 1947 22 1 3 1956 1959 1958 2 1964 65 2 10 1975 7080 70 2 1 1987 1990 40 1989 1989
More information立命館19_徳田.indd
1991-1022009 1 2 () )--) 28 2827 1 2 Key Words 1 (1721 2000 20012001 20082009 91 1920098 92 20042004 2004 2001 12 2005 20082009 2005 3 1997 200820096 2007 2 20082009 93 20012001 12 2008 2009 19611966 1
More information日本化学療法学会雑誌第56巻第S-1号
Key words Streptococcus pneumoniae µ µ H F Cl H H N N H N F COOH O Fig.1. Sitafloxacinstructure. I γ S. pneumoniae Haemophilus influenzae Table1. Observationandtestschedule Observation/Tests Informedconsent
More information日本化学療法学会雑誌第56巻第1号
β β β β β Streptococcus pneumoniaehaemophilus influenzaemoraxella catarrhalismycoplasma pneumoniaechlamydia pneumoniae β Key wordsβ mys nilc laci ngis Table. Assessmentschedule Parameters Patientcharacteristics
More information20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
More informationI? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
More information- 2 -
- 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -
More information2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1
1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4
More information1 (1) (2)
1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)
More informationTHE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
More information日本化学療法学会雑誌第56巻第4号
Key words I Number of xenobiotic transporters 25 20 5 0 5 0 Pseudomonas aeruginosa Escherichia coli Bacillus subtilis R MFS SMR MATE ABC Mycobacterium tuberculosis Fig.. Numberofputativedrugefluxgenesidentifiedby
More informationPerl + α. : DNA, mrna,,
2009 Perl + α. : DNA, mrna,, DNA .. DNA A C G T DNA 2 A-T, C-G DNA NH 2 NH 2 O - O O N P O - O CH 2 O N N O - O P O CH 2 O N O - O O P O NH 2 O - O - N CH 2 O N O OH OH OH DNA or RNA (U) (A) (G) (C)
More information日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
More informationFig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
More informationHOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly
HOE901 A S S Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Gly 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 S S S Phe Val Asn Gln His Leu Cys Gly Ser His Leu
More information日本化学療法学会雑誌第59巻第5号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S. pneumoniae H. influenzae M. catarrhalis S.
More information研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
More information1_alignment.ppt
" " " " n " n n " n " n n n " n n n n " n LGPSSKQTGKGW-SRIWDN! + +! LN-ITKSAGKGAIMRLGDA! " n -------TGKG--------!! -------AGKG--------! " n w w w " n w w " " " 11 12 " n w w w " n w w A! M! O! A!
More informationR06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
More information第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
More informationCHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
More informationuntitled
1 1 2 CADLIVE E-CELL 3 GEM CE/MS MGF WT MGF 4 2 WT E-Cell MASK 5 CE-MS, CE- TOFMS LC-MS 24, 5 9 2 0 6 3 CE-MS CE MS Soga, T. et al. (2002) Anal Chem. 74, 2233-2239 7 CE-MS 859 452, 269, 86 8 4 LC-MS 9
More information感染症学雑誌第77巻第8号
1 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ
More informationFeb THE JAPANESE JOURNAL OF ANTIBIOTICS ,4 2,4 2,4 2,3,4 2,3,4 2,3, ,3, Garenoxacin GRNX Levofloxacin LV
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 27 27 1,4 2,4 2,4 2,3,4 2,3,4 2,3,4 2 1 2,3,4 1 2 3 4 2015 10 21 9 Garenoxacin GRNX Levofloxacin LVFX Sitafloxacin STFX Moxifloxacin MFLX Pharmacokinetics-Pharmacodynamics
More informationStreptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
More information日本化学療法学会雑誌第57巻第S-2号
Key words β I Table. Observationandtestschedule Testschedule Observation/Tests Beforetreatment Endoftreatment 5 9days aftercompletion oftreatment 4 6weeks aftercompletion oftreatment Informedconsent Patientbackground
More information44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
More information1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
More information狂牛病調査第2巻1章,2章.doc
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 2.1 A LD50/30mg () 10 ND 1 2.8 ND ND ND 11 ND 2.3 1.0 ND ND 11 ND ND 1.3 1.7 ND 13 ND
More informationi ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
More information日本化学療法学会雑誌第57巻第S-2号
µ µ Key words µ µ µ I Table1. Subjectprofilesin(A)singleand(B)multiple-dosestudies (A)Single-dosestudy Age (yr) Height (cm) Bodyweight (kg) BMI (kg/m ) Ccr(Cockcroft) (ml/min) Ethnicity dose(mg) n 5 5.1±.,3
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More informationPolyoxometalateが有するcysteine検出能の検討及びジスルフィド結合形成反応への展開
チオールを特異的に酸化し 発色する 山形大学理工学研究科バイオ化学工学専攻准教授今野博行 金属酸化物クラスターアニオン ポリオキソメタレート Polyoxometalate (POM) 金属元素に酸素が6個配位した MO6を基本骨格とする金属酸化物 1 nm クラスターアニオン MO6 (octahedron) ( PxMyOz )n 構造 構成元素 対カチオン等を 制御することで 様々な機能性を
More informationŁRŁ¸•ñŁŁŁ‘
16 11 5 25mg 14 11 18 1 25mg 1 150,000 934 1 2 : 1-235-tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human γ1-chain Fc fragment), dimmer : : 1 235 236 467 G 1 γ1
More informationuntitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
More information366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
More information1
10 1113 14 1516 1719 20 21 22 2324 25 2627 i 2829 30 31 32 33 3437 38 3941 42 4344 4547 48 4950 5152 53 5455 ii 56 5758 59 6061 iii 1 2 3 4 5 6 7 8 9 10 PFI 30 20 10 PFI 11 12 13 14 15 10 11 16 (1) 17
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More information